Rosenstock J, Allison D, Birkenfeld A, Blicher T, Deenadayalan S, Jacobsen J, Serusclat P, Violante R, Watada H, Davies M
Eylea (aflibercept) Disease area(s): Ophthalmology Manufacturer(s): Regeneron/Bayer 2024 Sales (USD): $9.55 billion Why it sold so well: Eylea registered strong sales in 2024, driven by the introduction of Eylea HD, which received FDA approval in 2023 and is an 8 mg formulation offering extended dosing intervals for retinal diseases
demonstrated the protective effect of whey protein hydrolysate against oxidative damage caused by paracetamol (Reference Athira, Mann and Sharma15)
Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review
For women with PCOS, we already understand the androgen-driven component of your hair loss and can prescribe treatments like spironolactone that target it directly
W., Larsson, A., and Norgren, S